The MacDQoL individualised measure of the impact of macular degeneration on quality of life: reliability and responsiveness. [Macular Disease : Quality of Life]
American Journal of Ophthalmology 146 (3) 447-454. View article here.
Measuring quality of life in macular degeneration. [Macular Disease : Quality of Life]
In VA Preedy (Ed) Handbook of disease burdens and quality of life measures. Heidelberg: Springer-Vorlag (in press).
The MacDQoL individualized measure of the impact of macular disease on quality of life. [Macular Disease : Quality of Life]
Evaluating patients’ satisfaction with eye clinic services. [Macular Disease : Clinic/Service Satisfaction]
Digest, Journal of the Macular Disease Society, 20-21.
Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial. [Diabetes : Treatment Satisfaction]
The Lancet, 371 (9618), 1073-1084. View article here.
Improving treatment satisfaction and other patient-reported outcomes in people with Type 2 diabetes: the role of once-daily insulin glargine. [Diabetes : Treatment Satisfaction]
Diabetes, Obesity and Metabolism 10 (Suppl.2), 50-65. View article here.
Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. [Diabetes : Quality of Life]
Diabetes Care 31 (6) 1112-7. View article here.
© 2015 Health Psychology Research Ltd. Company no. 4803452
Website by NDP Studio